Evista (Raloxifene) 60 mg

The medical product Raloxifene (sold under name Evista), usually prescribed for preventive maintenance of a bony rarefication at women in the period after menopause, can also lower the risk of disease by cancer of a mammary gland at them almost on 70 % according to preliminary results presented at the annual assembly of the American Society of Clinical Oncology (ASCO).

Our bones of which a very few people thought before, now become the central problem on which the preservation of health depends. It is explained by the fact that more and more Americans live till 70, 80, and 90 years. For this reason, the condition of bones at each second woman and each eighth man essentially worsens, and their durability becomes insufficient for the maintenance of active independent life in the old age, a life which is not accompanied by crises and cracks, leading to physical inability.

As a result, the bony rarefication, i.e. the dystrophy of a bone fabric entailing a serious weakening of durability of bones, became a common word, known to everyone not less, than cholesterol. Accordingly, the American farmaceutical industry, the manufacturers of food additives, and since the recent time also the manufacturers of foodstuffs have responded to this problem by the release of special medicines and preparations, which help people not to be scattered apart while their natural life has not come to an end.

Evista, the unlicensed name — Raloxifene, is the first preparation of this group, which has been released on sale not so long ago. Evista activates the receptors of estrogen in bone fabric, not touching thus the receptors of a mammary gland, owing to what it becomes possible to prevent a bony rarefication at the women who have having contra-indications to the reception of estrogen. The lack of preparation is its competitive relations with its own estrogen, developed in an organism of the woman owing to what hot inflows amplify and the atrophy of walls of vagina proceeds. Due to the selective character of its action evista unlike estrogen does not protect the organism from cardiovascular diseases.

The company «Eli Lilly» has declared preliminary results of the trial Raloxifene Use of The Heart Trial (RUTH), a large-scale placebo-controllable trial, which was spent with the purpose of definition, whether the reception Evista®/ EvistaТМ (a raloxifene’s hydrochloride) reduces the risk of development of ischemic heart-disease and invasive cancer of a lung at women in the postmenopausal period with the diseases of cardiovascular system or high risk of development of an ischemic heart disease.

Evista® now it is approved in the USA for prevention of a bony rarefication and treatment of women with this disease during the postmenopause period. The participants of the trial were 10 000 patients from 26 countries, the period of supervision has made up 7 years. The preliminary analysis of the results of the trial on the two basic final points has testified, that the reception Evista® does not influence the frequency of fatal and not fatal aggravations of the diseases of the cardiovascular system and the sharp coronary syndrome leading to hospitalization.

Also in comparison with placebo Evista® has reduced the frequency of occurrence of the invasive cancer of a mammary gland. «As Evista® does not warn the development of the diseases of the cardiovascular system, we want to bring once again to attention of the doctors that the preparation should not be appointed for cardioprotection», — Alan Breyer, the vice-president and the head of the medical department of the company « Eli Lilly » has told.

«Doctors should be informed that according to the results of RUTH the moderate decrease in the level of lipoproteins of low density, revealed at earlier researches of a preparation and reflected in the instruction to Evista®, does not render influence on cardiac protection », — the representative of «Eli Lilly» has noted.

The daily use of raloxifene (Evista) during 8 years has caused a decrease in the risk of cancer of a mammary gland at women in postmenopause on 59 %, as it was reported at the 40-th Annual Congress of the American Society of Clinical Oncologists (ASCO).

” Long-term therapy with raloxifene does not increase the frequency of uterine bleedings or a cancer of a uterus “, adds Dr. Silvana Martino, the head of Breast Committee of the Southwest Oncology Group, Santa Monica, California.

However, Doctor Martino has paid attention to the fact that though the positive result is noted, raloxifene is not approved as the preparation for the prevention of cancer of a mammary gland. “It is impossible to give such recommendations until the direct comparative trials of raloxifene and tamoxifene will be carried out. There are already two such trials; their results are expected within the nearest years”, doctor Silvana Martino says.

Dr. Silvana Martino has also promulgated the results of two tests of the effect of raloxifene, the selective estrogen receptors’ modulator (SERM), for the mineral density by the way. On their basis, the Food and Drug Administration of the USA has approved raloxifene for treatment and prevention of a bony rarefication.

Contra-indications

• From the reproductive system: hypersensitivity, genital age, pregnancy, the period of lactation.
• From the cardiovascular system: thromboembolism (including thromboembolism in the anamnesis), thrombosis of deep veins, thrombosis of veins of the retina.
• Other: increased risk of vascular complications during pregnancy and lactation.

Collateral actions

• From the vascular system: vasodilatation (inflow of blood to the skin of the face), thromboembolism.
• From the musculoskeletal system: spasms of gastrocnemius muscles.
• Other: possible effects include altered circulation and increased risk of vascular events.